MST1 and neurodegenerative disease: In several neurodegenerative diseases, the Hippo signalling pathway is hyperactivated; therefore, it is feasible that chemical inhibitors modulating Hippo pathway components could be a therapeutic target for blocking neurodegeneration by manipulating the Hippo pathway through core kinases such as MST1/2 or by the effector YAP and its interaction with TEAD [118].